Synthesis and In Vitro Studies of Novel Pyrimidinyl Peptidomimetics as Potential Antimalarial Therapeutic Agents
Identifieur interne : 002163 ( Main/Exploration ); précédent : 002162; suivant : 002164Synthesis and In Vitro Studies of Novel Pyrimidinyl Peptidomimetics as Potential Antimalarial Therapeutic Agents
Auteurs : Shuren Zhu [États-Unis] ; Thomas H. Hudson [États-Unis] ; Dennis E. Kyle [États-Unis] ; Ai J. Lin [États-Unis, Israël]Source :
- Journal of Medicinal Chemistry [ 0022-2623 ] ; 2002.
Abstract
A class of new pyrimidinyl peptidomimetic agents (compounds 1−6) were synthesized, and their in vitro antimalarial activities against Plasmodium falciparum were evaluated. The core structure of the new agents consists of a substituted 5-aminopyrimidone ring and a Michael acceptor side chain methyl 2-hydroxymethyl-but-2-enoate. The synthesis of 1−6 featured a Baylis−Hillman reaction of various aldehydes with methyl acrylate catalyzed by 1,4-diazabicyclo[2.2.2]octane (DABCO) and a SN2‘ Mitsunobu reaction under the conditions of diethyl azadicarboxylate (DEAD), triphenylphosphine (Ph3P), and various acids. The new compounds exhibited potent in vitro growth inhibitory activity (IC 50 = 10−30 ng/mL) against both chloroquine sensitive (D-6) and chloroquine resistant (W-2) Plasmodium falciparum clones. Compound 6 (IC50 = 6−8 ng/mL) is the most active compound of the class, the antimalarial efficacy of which is comparable to that of chloroquine. In general, this class of compound exhibited weak to moderate in vitro cytotoxicity against neuronal and macrophage cells with IC 50 in the range of 1−16 μg/mL and showed less toxicity in a colon cell line. Preliminary results indicated that compounds 3 and 6 are active against P. berghei, prolonged the life span of parasite-bearing mice from 6 days for untreated control to 16−24 days for drug-treated animals.
Url:
DOI: 10.1021/jm020104f
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000755
- to stream Istex, to step Curation: 000755
- to stream Istex, to step Checkpoint: 000F90
- to stream Main, to step Merge: 002185
- to stream Main, to step Curation: 002163
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Synthesis and In Vitro Studies of Novel Pyrimidinyl Peptidomimetics as Potential Antimalarial Therapeutic Agents</title><author><name sortKey="Zhu, Shuren" sort="Zhu, Shuren" uniqKey="Zhu S" first="Shuren" last="Zhu">Shuren Zhu</name></author><author><name sortKey="Hudson, Thomas H" sort="Hudson, Thomas H" uniqKey="Hudson T" first="Thomas H." last="Hudson">Thomas H. Hudson</name></author><author><name sortKey="Kyle, Dennis E" sort="Kyle, Dennis E" uniqKey="Kyle D" first="Dennis E." last="Kyle">Dennis E. Kyle</name></author><author><name sortKey="Lin, Ai J" sort="Lin, Ai J" uniqKey="Lin A" first="Ai J." last="Lin">Ai J. Lin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1FD332E90F9395BD697F6111BB07FA919892FD44</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1021/jm020104f</idno><idno type="url">https://api.istex.fr/ark:/67375/TPS-K8GHX6Z8-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000755</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000755</idno><idno type="wicri:Area/Istex/Curation">000755</idno><idno type="wicri:Area/Istex/Checkpoint">000F90</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F90</idno><idno type="wicri:doubleKey">0022-2623:2002:Zhu S:synthesis:and:in</idno><idno type="wicri:Area/Main/Merge">002185</idno><idno type="wicri:Area/Main/Curation">002163</idno><idno type="wicri:Area/Main/Exploration">002163</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Synthesis and In Vitro Studies of Novel Pyrimidinyl Peptidomimetics as
Potential Antimalarial Therapeutic Agents</title><author><name sortKey="Zhu, Shuren" sort="Zhu, Shuren" uniqKey="Zhu S" first="Shuren" last="Zhu">Shuren Zhu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue,Silver Spring</wicri:cityArea></affiliation></author><author><name sortKey="Hudson, Thomas H" sort="Hudson, Thomas H" uniqKey="Hudson T" first="Thomas H." last="Hudson">Thomas H. Hudson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue,Silver Spring</wicri:cityArea></affiliation></author><author><name sortKey="Kyle, Dennis E" sort="Kyle, Dennis E" uniqKey="Kyle D" first="Dennis E." last="Kyle">Dennis E. Kyle</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue,Silver Spring</wicri:cityArea></affiliation></author><author><name sortKey="Lin, Ai J" sort="Lin, Ai J" uniqKey="Lin A" first="Ai J." last="Lin">Ai J. Lin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue,Silver Spring</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Israël</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medicinal Chemistry</title><title level="j" type="abbrev">J. Med. Chem.</title><idno type="ISSN">0022-2623</idno><idno type="eISSN">1520-4804</idno><imprint><publisher>American Chemical Society</publisher><date type="e-published" when="2002-07-09">2002</date><date when="2002-08-01">2002</date><biblScope unit="vol">45</biblScope><biblScope unit="issue">16</biblScope><biblScope unit="page" from="3491">3491</biblScope><biblScope unit="page" to="3496">3496</biblScope></imprint><idno type="ISSN">0022-2623</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-2623</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">A class of new pyrimidinyl peptidomimetic agents (compounds 1−6) were synthesized, and their in vitro antimalarial activities against Plasmodium falciparum were evaluated. The core structure of the new agents consists of a substituted 5-aminopyrimidone ring and a Michael acceptor side chain methyl 2-hydroxymethyl-but-2-enoate. The synthesis of 1−6 featured a Baylis−Hillman reaction of various aldehydes with methyl acrylate catalyzed by 1,4-diazabicyclo[2.2.2]octane (DABCO) and a SN2‘ Mitsunobu reaction under the conditions of diethyl azadicarboxylate (DEAD), triphenylphosphine (Ph3P), and various acids. The new compounds exhibited potent in vitro growth inhibitory activity (IC 50 = 10−30 ng/mL) against both chloroquine sensitive (D-6) and chloroquine resistant (W-2) Plasmodium falciparum clones. Compound 6 (IC50 = 6−8 ng/mL) is the most active compound of the class, the antimalarial efficacy of which is comparable to that of chloroquine. In general, this class of compound exhibited weak to moderate in vitro cytotoxicity against neuronal and macrophage cells with IC 50 in the range of 1−16 μg/mL and showed less toxicity in a colon cell line. Preliminary results indicated that compounds 3 and 6 are active against P. berghei, prolonged the life span of parasite-bearing mice from 6 days for untreated control to 16−24 days for drug-treated animals.</div></front></TEI><affiliations><list><country><li>Israël</li><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Zhu, Shuren" sort="Zhu, Shuren" uniqKey="Zhu S" first="Shuren" last="Zhu">Shuren Zhu</name></region><name sortKey="Hudson, Thomas H" sort="Hudson, Thomas H" uniqKey="Hudson T" first="Thomas H." last="Hudson">Thomas H. Hudson</name><name sortKey="Kyle, Dennis E" sort="Kyle, Dennis E" uniqKey="Kyle D" first="Dennis E." last="Kyle">Dennis E. Kyle</name><name sortKey="Lin, Ai J" sort="Lin, Ai J" uniqKey="Lin A" first="Ai J." last="Lin">Ai J. Lin</name></country><country name="Israël"><noRegion><name sortKey="Lin, Ai J" sort="Lin, Ai J" uniqKey="Lin A" first="Ai J." last="Lin">Ai J. Lin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002163 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002163 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1FD332E90F9395BD697F6111BB07FA919892FD44
|texte= Synthesis and In Vitro Studies of Novel Pyrimidinyl Peptidomimetics as Potential Antimalarial Therapeutic Agents
}}
| This area was generated with Dilib version V0.6.33. |  |